Clinical Trials Logo

Clinical Trial Summary

This study is a phase 2/3 clinical trial to evaluate the efficacy and safety of SHR-1703 in patients with EGPA.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05979051
Study type Interventional
Source Guangdong Hengrui Pharmaceutical Co., Ltd
Contact Siai Sun
Phone 0518-82342973
Email siai.sun@hengrui.com
Status Recruiting
Phase Phase 2/Phase 3
Start date November 16, 2023
Completion date May 16, 2027

See also
  Status Clinical Trial Phase
Recruiting NCT02967068 - VCRC Tissue Repository
Recruiting NCT05030155 - Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge) Phase 3
Active, not recruiting NCT03164473 - Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. Phase 3
Recruiting NCT05263934 - Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Phase 3
Recruiting NCT02006134 - Pediatric Vasculitis Initiative
Recruiting NCT06046222 - Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis Phase 2
Completed NCT04280601 - PRagmatic Analysis of Vitamin D in ANCA-Associated Vasculitis N/A
Not yet recruiting NCT06231498 - The Epigenomic Signature of Eosinophilic Granulomatosis With Polyangiitis
Recruiting NCT00315380 - Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss)
Completed NCT03298061 - Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921 Phase 3